Chapter 10 NF‐κB as a Determinant of Distinct Cell Death Pathways

Author(s):  
Irene L. Ch'en ◽  
Stephen M. Hedrick ◽  
Alexander Hoffmann
Author(s):  
Gloria Elisa Villalpando Rodriguez ◽  
Anna Blankstein ◽  
Elizabeth S. Henson ◽  
Spencer B. Gibson

Glioblastoma is inherently resistant to radiation and drug treatments. This is mediated by the most common forms of cell death are often actively inhibited. Identifying and exploiting alternative cell death pathways are essential to overcoming or bypassing drug resistance. Ferroptosis, a newly described, morphologically and biochemically distinct, cell death mechanism is characterized by iron-dependent cellular accumulation of reactive oxygen species. The combination of siramesine, a lysosome disruptor, and lapatinib, a dual tyrosine kinase inhibitor (TKI), synergistically induced death in glioma cancer cells. This cell death had characteristics of ferroptosis: it was blocked by the ferroptosis inhibitor ferrostatin-1 and the iron chelator deferoxamine. In addition, the amount of ROS and lipid peroxidation were increased in glioma cells. Iron transport protein remained unchanged but reactive iron levels increased. One target for kinase inhibitors is protein bisulfate isomerase (PDI). Knockdown of PDI in combination with siramesine increased cell death that was blocked by ferrostatin-1. Taken together, drug combinations that alter reactive iron and ROS levels might induce ferroptosis and overcome drug resistance in glioma cells.


2018 ◽  
Vol 59 (1) ◽  
pp. 351-359 ◽  
Author(s):  
Angelo Spinello ◽  
Elena Vecile ◽  
Antonio Abbate ◽  
Aldo Dobrina ◽  
Alessandra Magistrato

2017 ◽  
Vol 189 (1) ◽  
pp. 68 ◽  
Author(s):  
Justin Steinman ◽  
Michael Epperly ◽  
Wen Hou ◽  
John Willis ◽  
Hong Wang ◽  
...  

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Oleg Lunov ◽  
Vitalii Zablotskii ◽  
Olexander Churpita ◽  
Mariia Lunova ◽  
Milan Jirsa ◽  
...  

2009 ◽  
Vol 253 (1-2) ◽  
pp. 32-41 ◽  
Author(s):  
Kelly N. Owens ◽  
Allison B. Coffin ◽  
Lisa S. Hong ◽  
Keri O’Connell Bennett ◽  
Edwin W Rubel ◽  
...  

2020 ◽  
Vol 26 (26) ◽  
pp. 5903-5910 ◽  
Author(s):  
Liang Chen ◽  
Yu Fan ◽  
Jieru Qiu ◽  
Régis Laurent ◽  
Jin Li ◽  
...  

2021 ◽  
Vol 1 (4) ◽  
pp. 223-228
Author(s):  
Rushikesh Deshpande ◽  
Chunbin Zou

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the latest variant in the coronavirus family, causing COVID-19, has resulted in global pandemic since early 2020 leading to severe public health concern. So far, the pandemic has caused more than 200 million infections and 4 million deaths worldwide. Most of the studies are focused on developing prevention, intervention, and therapeutic strategies. However, underlying pathophysiology of the disease is important as well, which needs further attention. Cell death is one of the major causative mechanisms that leads to severe inflammation, and it is also an a posteriori consequence of the hyperinflammatory storm that renders poor prognosis of the disease. Substantial cell death has been reported in biopsy samples from post mortem patients. Among the distinct cell death pathways, apoptosis, the regulated programmed cell death plays an important role in the pathogenesis of the disease. Understanding the role of SARS-CoV-2 infection in apoptosis is critical to linearize the pathogenesis of the virus as well as the resultant disease, that may uncover novel therapeutic targets in treatment of COVID-19 patients. Here, we review the current progress on the underlying molecular mechanism(s) of SARS-CoV-2-induced apoptosis, not only at the level of the virus but also at its individual proteins.


Molecules ◽  
2021 ◽  
Vol 26 (23) ◽  
pp. 7200
Author(s):  
Uyanga Batbold ◽  
Jun-Jen Liu

Conventional chemotherapy remains an integral part of lung cancer therapy, regardless of its toxicity and drug resistance. Consequently, the discovery of an alternative to conventional chemotherapy is critical. Artemisia santolinifolia ethanol extract (AS) was assessed for its chemosensitizer ability when combined with the conventional anticancer drug, docetaxel (DTX), against non-small cell lung cancer (NSCLC). SRB assay was used to determine cell viability for A549 and H23 cell lines. The potential for this combination was examined by the combination index (CI). Further cell death, analyses with Annexin V/7AAD double staining, and corresponding protein expressions were analyzed. Surprisingly, AS synergistically enhanced the cytotoxic effect of DTX by inducing apoptosis in H23 cells through the caspase-dependent pathway, whereas selectively increased necrotic cell population in A549 cells, following the decline in GPX4 level and reactive oxygen species (ROS) activation with the highest rate in the combination treatment group. Furthermore, our results highlight the chemosensitization ability of AS when combined with DTX. It was closely associated with synergistic inhibition of oncogenesis signaling molecule STAT3 in both cell lines and concurrently downregulating prosurvival protein Survivin. Conclusively, AS could enhance DTX-induced cancer cells apoptosis by abrogating substantial prosurvival proteins’ expressions and triggering two distinct cell death pathways. Our data also highlight that AS might serve as an adjunctive therapeutic option along with a conventional chemotherapeutic agent in the management of NSCLC patients.


2020 ◽  
Vol 48 (3) ◽  
pp. 137-152
Author(s):  
Marko Manevski ◽  
Dinesh Devadoss ◽  
Ruben Castro ◽  
Lauren Delatorre ◽  
Adriana Yndart ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document